Many chemotherapy drugs used for treating breast cancer are given in liquid form, as intravenous (IV, into the vein) infusions or injections (into the skin), but some are available as pills or tablets.2 Some drugs may be given alone, and other drugs are combined to work together. When ch...
Many women presenting with Stage 11 or III breast cancer will relapse following initial adjuvant therapy. As current standard therapy will not cure patients with metastatic disease, dose intensification and new cytotoxic agents are being studied extensively. These new agents include vinorelbine, ...
Gene therapy for breast cancer initially involves local or systemic delivery. Local delivery may be intrapleural or via direct injection to lesions. However, systemic delivery remains the greatest challenge with targeting, although methods using antibodies or growth factor receptor ligands have been demon...
Chemotherapydrugs called anthracyclines -- prescribed to treat many types ofbreast cancer-- have been linked with memory issues in the past. But now a large new study has found no evidence that those drugs increase the risk of memory problems or other cognitive decline. UCLA researchers analyzed ...
that can facilitate the seeding and growth of metastatic cancer cells in distant organs, but the effects of chemotherapy on tumour-derived EVs remain unclear. Here we show that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyc...
Chemotherapy drugs use powerful chemicals to kill cancer cells and inhibit them from reproducing and spreading throughout the body. Most often, these medications are very effective at what they do – but they can also be a little too effective, destroyi
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat. 2018;169(1):175-187. doi:10.1007/s10549-017-4646-1 PubMedGoogle ScholarCrossref 29. U.S...
Dr Haywood consults for the economic evaluations for the Australian Pharmaceutical Benefits Advisory Committee (PBAC). Professor Ward serves on two Commonwealth committees (the PBAC and the Medical Services Advisory Committee of Australia), which advise Government on the funding of services and drugs. ...
Single immunotherapy fails to demonstrate efficacy in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Research on immune reactions before and after systemic agents for mCRC is warranted. Our study examined cell line models to compare the expression of immune surface marke...
Ten-percent (41/358) of the genes on the panel are identified as causal, 53% (172/358) are targeted by drugs and/or causal, and the remaining 37% (145/358) are research grade. Genes in tiers one and two were further annotated to signaling pathways involved in efficacy of targeted ...